Hyperprolactinaemia, a common side effect of some antipsychotic drugs, is also present in drug-na？ve psychotic patients and subjects at risk for psychosis. Recent studies in non-psychiatric populations suggest that increased prolactin may have negative effects on cognition. The aim of our study was to explore whether high plasma prolactin levels are associated with poorer cognitive functioning in subjects with early psychoses. We studied 107 participants: 29 healthy subjects and 78 subjects with an early psychosis (55 psychotic disorders with <3 years of illness, 23 high-risk subjects). Cognitive assessment was performed with the MATRICS Cognitive Consensus Cognitive Battery, and prolactin levels were determined as well as total cortisol levels in plasma. Psychopathological status was assessed and the use of psychopharmacological treatments (antipsychotics, antidepressants, benzodiazepines) recorded. Prolactin levels were negatively associated with cognitive performance in processing speed, in patients with a psychotic disorder and high-risk subjects. In the latter group, increased prolactin levels were also associated with impaired reasoning and problem solving and poorer general cognition. In a multiple linear regression analysis conducted in both high-risk and psychotic patients, controlling for potential confounders, prolactin and benzodiazepines were independently related to poorer cognitive performance in the speed of processing domain. A mediation analysis showed that both prolactin and benzodiazepine treatment act as mediators of the relationship between risperidone/paliperidone treatment and speed of processing. These results suggest that increased prolactin levels are associated with impaired processing speed in early psychosis. If these results are confirmed in future studies, strategies targeting reduction of prolactin levels may improve cognition in this population.
References
[1]
Fitzgerald P, Dinan TG (2008) Prolactin and dopamine: What is the connection? A review article. J Psychopharmacol 22: 12–19. doi: 10.1177/0269216307087148
[2]
Inder WJ, Castle D (2011) Antipsychotic-induced hyperprolactinaemia. Aust N Z J Psychiatry 45: 830–837. doi: 10.3109/00048674.2011.589044
[3]
Aston J, Rechsteiner E, Bull N, Borgwardt S, Gschwandtner U, et al. (2010) Hyperprolactinaemia in early psychosis-not only due to antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 34: 1342–1344. doi: 10.1016/j.pnpbp.2010.02.019
[4]
Garcia-Rizo C, Fernandez-Egea E, Oliveira C, Justicia A, Parellada E, et al. (2012) Prolactin concentrations in newly diagnosed, antipsychotic-naive patients with nonaffective psychosis. Schizophr Res 134: 16–19. doi: 10.1016/j.schres.2011.07.025
[5]
Riecher-Rossler A, Rybakowski JK, Pflueger MO, Beyrau R, Kahn RS, et al. (2013) Hyperprolactinemia in antipsychotic-naive patients with first-episode psychosis. Psychol Med : 1–12.
[6]
Lennartsson AK, Jonsdottir IH (2011) Prolactin in response to acute psychosocial stress in healthy men and women. Psychoneuroendocrinology 36: 1530–1539. doi: 10.1016/j.psyneuen.2011.04.007
[7]
Halbreich U, Kahn LS (2003) Hyperprolactinemia and schizophrenia: Mechanisms and clinical aspects. J Psychiatr Pract 9: 344–353. doi: 10.1097/00131746-200309000-00003
[8]
Johnsen E, Kroken R, Loberg EM, Kjelby E, Jorgensen HA (2011) Sexual dysfunction and hyperprolactinemia in male psychotic inpatients: A cross-sectional study. Adv Urol 2011: 686924. doi: 10.1155/2011/686924
[9]
Henry JF, Sherwin BB (2012) Hormones and cognitive functioning during late pregnancy and postpartum: A longitudinal study. Behav Neurosci 126: 73–85. doi: 10.1037/a0025540
[10]
Torner L, Tinajero E, Lajud N, Quintanar-Stephano A, Olvera-Cortes E (2013) Hyperprolactinemia impairs object recognition without altering spatial learning in male rats. Behav Brain Res 252: 32–39. doi: 10.1016/j.bbr.2013.05.031
[11]
Sherwin BB (2012) Estrogen and cognitive functioning in women: Lessons we have learned. Behav Neurosci 126: 123–127. doi: 10.1037/a0025539
[12]
Wolf OT, Kirschbaum C (2002) Endogenous estradiol and testosterone levels are associated with cognitive performance in older women and men. Horm Behav 41: 259–266. doi: 10.1006/hbeh.2002.1770
[13]
Bilder RM, Goldman RS, Robinson D, Reiter G, Bell L, et al. (2000) Neuropsychology of first-episode schizophrenia: Initial characterization and clinical correlates. Am J Psychiatry 157: 549–559. doi: 10.1176/appi.ajp.157.4.549
[14]
Heinrichs RW, Zakzanis KK (1998) Neurocognitive deficit in schizophrenia: A quantitative review of the evidence. Neuropsychology 12: 426–445. doi: 10.1037//0894-4105.12.3.426
[15]
Davidson M, Reichenberg A, Rabinowitz J, Weiser M, Kaplan Z, et al. (1999) Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents. Am J Psychiatry 156: 1328–1335.
[16]
Reichenberg A, Weiser M, Rapp MA, Rabinowitz J, Caspi A, et al. (2005) Elaboration on premorbid intellectual performance in schizophrenia: Premorbid intellectual decline and risk for schizophrenia. Arch Gen Psychiatry 62: 1297–1304. doi: 10.1001/archpsyc.62.12.1297
[17]
Green MF (1996) What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 153: 321–330.
[18]
Cuesta MJ, Garcia de Jalon E, Campos MS, Ibanez B, Sanchez-Torres AM, et al. (2012) Duration of untreated negative and positive symptoms of psychosis and cognitive impairment in first episode psychosis. Schizophr Res 141: 222–227. doi: 10.1016/j.schres.2012.08.019
[19]
Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, et al. (2002) Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 159: 1018–1028. doi: 10.1176/appi.ajp.159.6.1018
[20]
Purdon SE, Malla A, Labelle A, Lit W (2001) Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiatry Neurosci 26: 137–149. doi: 10.1016/s0920-9964(00)90808-9
[21]
Harvey PD (2003) Ziprasidone and cognition: The evolving story. J Clin Psychiatry 64 Suppl 1933–39.
[22]
Keefe RS, Seidman LJ, Christensen BK, Hamer RM, Sharma T, et al. (2004) Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: A randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry 161: 985–995. doi: 10.1176/appi.ajp.161.6.985
[23]
Chew ML, Mulsant BH, Pollock BG, Lehman ME, Greenspan A, et al. (2006) A model of anticholinergic activity of atypical antipsychotic medications. Schizophr Res 88: 63–72. doi: 10.1016/j.schres.2006.07.011
[24]
Mishara AL, Goldberg TE (2004) A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: Opening a closed book. Biol Psychiatry 55: 1013–1022. doi: 10.1016/j.biopsych.2004.01.027
[25]
Woodward ND, Purdon SE, Meltzer HY, Zald DH (2007) A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: Dose effects and comparison to practice effects. Schizophr Res 89: 211–224. doi: 10.1016/j.schres.2006.08.021
[26]
Maguire GA (2002) Prolactin elevation with antipsychotic medications: Mechanisms of action and clinical consequences. J Clin Psychiatry 63 Suppl 456–62.
[27]
Cookson J, Hodgson R, Wildgust HJ (2012) Prolactin, hyperprolactinaemia and antipsychotic treatment: A review and lessons for treatment of early psychosis. J Psychopharmacol 26: 42–51. doi: 10.1177/0269881112442016
[28]
Harvey PD, Keefe RS (2001) Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 158: 176–184. doi: 10.1176/appi.ajp.158.2.176
[29]
Keefe RS, Silva SG, Perkins DO, Lieberman JA (1999) The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: A review and meta-analysis. Schizophr Bull 25: 201–222. doi: 10.1093/oxfordjournals.schbul.a033374
[30]
Carpenter WT, Gold JM (2002) Another view of therapy for cognition in schizophrenia. Biol Psychiatry 51: 969–971. doi: 10.1016/s0006-3223(02)01399-9
[31]
Yung AR, Phillips LJ, McGorry PD, McFarlane CA, Francey S, et al. (1998) Prediction of psychosis. A step towards indicated prevention of schizophrenia. Br J Psychiatry Suppl 172: 14–20.
[32]
Wing JK, Babor T, Brugha T, Burke J, Cooper JE, et al. (1990) SCAN. schedules for clinical assessment in neuropsychiatry. Arch Gen Psychiatry 47: 589–593. doi: 10.1001/archpsyc.1990.01810180089012
[33]
Kay SR, Fiszbein A, Vital-Herne M, Fuentes LS (1990) The positive and negative syndrome scale–spanish adaptation. J Nerv Ment Dis 178: 510–517. doi: 10.1097/00005053-199008000-00007
[34]
Addington D, Addington J, Schissel B (1990) A depression rating scale for schizophrenics. Schizophr Res 3: 247–251. doi: 10.1016/0920-9964(90)90005-r
[35]
Gardner DM, Murphy AL, O’Donnell H, Centorrino F, Baldessarini RJ (2010) International consensus study of antipsychotic dosing. Am J Psychiatry 167: 686–693. doi: 10.1176/appi.ajp.2009.09060802
[36]
Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, et al. (2008) The MATRICS consensus cognitive battery, part 1: Test selection, reliability, and validity. Am J Psychiatry 165: 203–213. doi: 10.1176/appi.ajp.2007.07010042
[37]
Rodriguez-Jimenez R, Bagney A, Garcia-Navarro C, Aparicio AI, Lopez-Anton R, et al. (2012) The MATRICS consensus cognitive battery (MCCB): Co-norming and standardization in spain. Schizophr Res 134: 279–284. doi: 10.1016/j.schres.2011.11.026
[38]
Baron RM, Kenny DA (1986) The moderator-mediator variable distinction in social psychological research: Conceptual, strategic, and statistical considerations. J Pers Soc Psychol 51: 1173–1182. doi: 10.1037/0022-3514.51.6.1173
[39]
Shrout PE, Bolger N (2002) Mediation in experimental and nonexperimental studies: New procedures and recommendations. Psychol Methods 7: 422–445. doi: 10.1037//1082-989x.7.4.422
[40]
Preacher KJ, Hayes AF (2008) Asymptotic and resampling strategies for assessing and comparing indirect effects in multiple mediator models. Behav Res Methods 40: 879–891. doi: 10.3758/brm.40.3.879
[41]
Dickinson D, Ramsey ME, Gold JM (2007) Overlooking the obvious: A meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia. Arch Gen Psychiatry 64: 532–542. doi: 10.1001/archpsyc.64.5.532
[42]
Riecher-Rossler A, Pflueger MO, Aston J, Borgwardt SJ, Brewer WJ, et al. (2009) Efficacy of using cognitive status in predicting psychosis: A 7-year follow-up. Biol Psychiatry 66: 1023–1030. doi: 10.1016/j.biopsych.2009.07.020
[43]
Ojeda N, Pena J, Sanchez P, Elizagarate E, Ezcurra J (2008) Processing speed mediates the relationship between verbal memory, verbal fluency, and functional outcome in chronic schizophrenia. Schizophr Res 101: 225–233. doi: 10.1016/j.schres.2007.12.483
[44]
Dickinson D (2008) Digit symbol coding and general cognitive ability in schizophrenia: Worth another look? Br J Psychiatry 193: 354–356. doi: 10.1192/bjp.bp.108.049387
[45]
Kelleher I, Murtagh A, Clarke MC, Murphy J, Rawdon C, et al. (2012) Neurocognitive performance of a community-based sample of young people at putative ultra high risk for psychosis: Support for the processing speed hypothesis. Cogn Neuropsychiatry.
[46]
Fusar-Poli P, Bonoldi I, Yung AR, Borgwardt S, Kempton MJ, et al. (2012) Predicting psychosis: Meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry 69: 220–229. doi: 10.1001/archgenpsychiatry.2011.1472
[47]
Lee BJ, Lee SJ, Kim MK, Lee JG, Park SW, et al. (2013) Effect of aripiprazole on cognitive function and hyperprolactinemia in patients with schizophrenia treated with risperidone. Clin Psychopharmacol Neurosci 11: 60–66. doi: 10.9758/cpn.2013.11.2.60
[48]
Stewart SA (2005) The effects of benzodiazepines on cognition. J Clin Psychiatry 66 Suppl 29–13.
[49]
Zhang X, Bu R, Sha W, Wang X, Liu J, et al. (2013) Serum prolactin and smoking status in chronic antipsychotic-treated male patients with schizophrenia. Psychiatry Res 209: 239–241. doi: 10.1016/j.psychres.2013.04.026
[50]
Segarra R, Zabala A, Eguiluz JI, Ojeda N, Elizagarate E, et al. (2011) Cognitive performance and smoking in first-episode psychosis: The self-medication hypothesis. Eur Arch Psychiatry Clin Neurosci 261: 241–250. doi: 10.1007/s00406-010-0146-6
